Use of PARP Inhibitors for Ovarian Cancer
The data on PARP inhibitors for treatment of ovarian, primary peritoneal, or fallopian tube cancers has led to substantial changes in the recommendations for molecular testing, maintenance after first-line therapy, recurrence therapy, and maintenance after recurrence therapy.
  • Ovarian Cancer
  • Recorded Webcast
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation